ArticleFrontiers in psychiatry2026
Mechanisms of Changma Xifeng tablet in alleviating Tourette syndrome via modulation of neurotransmitters, inflammatory responses, and metabolic pathways.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tourette syndrome (TS) is a common pediatric neurodevelopmental disorder. Changma Xifeng tablet (CMXF), a traditional Chinese medicinal formulation, is widely used clinically for TS but its mechanisms remain unclear. This study aimed to evaluate CMXF's efficacy and explore its action mechanisms via a TS murine model. Methods: The chemical constituents of CMXF were analyzed and identified by UPLC-Q-TOF-MS/MS. Sixty male BALB/c mice were divided into 6 groups (CON, MOD, HAL, CMXF-L/M/H). TS models were induced by IDPN injection. Behavioral assessments, ELISA (neurotransmitters/inflammatory cytokines), HE staining (striatal pathology), RT-qPCR/WB (DRD1/DRD2/COMT/MAO-B), and UHPLC-Q-TOF LC-MS (serum metabolomics) were performed. Results: A total of twenty-one components, including gallic acid, gastrodin, catechin, sibiricose A3, paeoniflorin, parishin B, and tenuifoliside B, were identified in CMXF. From week 4 to week 8, the HAL group and CMXF-H group showed significantly improved behavioral performance compared with the MOD group ( Discussion: CMXF exerts anti-TS effects by regulating neurotransmitters, inflammatory cytokines, DA signaling, and serum metabolites, providing novel insights into its mechanisms and potential targeted therapy for TS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.